Phenotypic APC Resistance in Carriers of the A20210 Prothrombin Mutation Is Associated with an Increased Risk of Venous Thrombosis

Summary We hypothesized that increased prothrombin levels associated with G20210A prothrombin gene mutation could affect the results of activated protein C (APC) resistance phenotype and increase the risk of venous thrombosis (VT). The increasing addition of purified prothrombin in plasma of 90 normal subjects resulted in a parallel significant increase of APC resistance. Significantly different mean n-APC-SR in 879 GG20210 subjects compared to 27 heterozygous carriers of isolated G20210A mutation was observed (1.0 ± 0.12 vs. 0.95 ± 0.11; P = 0.02) in a random sample of 906 normal population subjects. Twenty-seven families with VT and isolated G20210A mutation consecutively diagnosed during 1998-1999 were evaluated. Mean n-APC-SR was significantly lower in the 80 G20210A carriers compared to 58 GG 20210 relatives investigated, even after sex and age adjustment (0.92 ± 0.08 vs. 1.05 ± 0.13; P < 0.0001). A strong relationship between plasma prothrombin level and n-APC-SR was observed in the families. When n-APC-SR values were grouped in tertiles, the odds ratio for VTE, after exclusion of the index cases and adjustment for 20210 status, for subjects in the lowest tertile (n-APC-SR 0.73-0.90) was 4.58 (95% CI 0.78-26.88) compared to upper tertile (n-APC-SR 1.01-1.30). In conclusion, in subjects with G20210A mutation APC resistance is significantly increased, correlates with plasma prothrombin level and the carriers with the lowest APC resistance values have an increased risk of VTE.

[1]  P. Mannucci,et al.  Hyperprothrombinemia may result in acquired activated protein C resistance , 2000 .

[2]  L. Almasy,et al.  Linkage analysis demonstrates that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis. , 2000, Blood.

[3]  S. Humphries,et al.  Prothrombin Activation Is Increased among Asymptomatic Carriers of the Prothrombin G20210A and Factor V Arg506Gln Mutations , 2000, Thrombosis and Haemostasis.

[4]  C. Esmon,et al.  HEMOSTASIS , THROMBOSIS , AND VASCULAR BIOLOGY Inhibition of Activated Protein C Anticoagulant Activity by Prothrombin By , 1999 .

[5]  A. Tosetto,et al.  The VITA Project: Prothrombin G20210A Mutation and Venous Thromboembolism in the General Population , 1999, Thrombosis and Haemostasis.

[6]  A. Tosetto,et al.  Activated Protein C Resistance and Factor V Leiden Mutation Are Independent Risk Factors for Venous Thromboembolism , 1999, Annals of Internal Medicine.

[7]  F. Rosendaal,et al.  A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. , 1999, Blood.

[8]  A. Tosetto,et al.  The VITA Project: Phenotypic Resistance to Activated Protein C and FV Leiden Mutation in the General Population , 1997, Thrombosis and Haemostasis.

[9]  A. Cumming,et al.  The prothrombin gene G20210A variant: prevalence in a U.K. anticoagulant clinic population , 1997, British journal of haematology.

[10]  P. Mannucci,et al.  Screening for the FV: Q506 Mutation – Evaluation of Thirteen Plasma-based Methods for their Diagnostic Efficacy in Comparison with DNA Analysis , 1997, Thrombosis and Haemostasis.

[11]  A. Tosetto,et al.  The Epidemiology of lnherited Thrombophilia: the VITA Project , 1997, Thrombosis and Haemostasis.

[12]  P. Reitsma,et al.  A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. , 1996, Blood.

[13]  A. Tosetto,et al.  The VITA Project: Population-based Distributions of Protein C, Antithrombin III, Heparin-cofactor II and Plasminogen -Relationship with Physiological Variables and Establishment of Reference Ranges , 1996, Thrombosis and Haemostasis.

[14]  P. Reitsma,et al.  Resistance to Activated Protein C and Factor V Leiden as Risk Factors for Venous Thrombosis , 1995, Thrombosis and Haemostasis.

[15]  P. Reitsma,et al.  High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance) , 1995, Blood.

[16]  K. Radtke,et al.  Acquired Activated Protein C-Resistance in Patients with Lupus Anticoagulants , 1995, Thrombosis and Haemostasis.

[17]  J. Vandenbroucke,et al.  Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis , 1995, The Lancet.

[18]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[19]  S. Jane,et al.  Inhibition of the anticoagulant activity of protein S by prothrombin. , 1988, The Journal of clinical investigation.